Clinical trials: Radiation Dosage
Hepatocellular Carcinoma
TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA.
The TheraSphere Post-Approval Study is a post-market, prospective, single-arm, open-label, observational study to support the use of TheraSphere for the treatment of hepatocellular carcinoma (HCC).
- Trial name
- NCT05233098
- Testing
- Technetium-99m macroaggregated albumin (Tc-99m MAA)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Boston Scientific Corporation
Glioblastoma Multiforme
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
The purpose of this study is to evaluate the safety, maximum tolerated dose (MTD), and efficacy of TPI 287 in combination with Avastin (bevacizumab) in subjects who have glioblastoma multiforme (GBM) that has progressed following…
- Trial name
- NCT02047214
- Testing
- TPI 287, Bevacizumab
- Where
- 11 sites in United States
- Volunteers
- 17 people
- Sponsor
- Cortice Biosciences, Inc.
Carcinoma, Non-Small-Cell Lung
Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED)
This is a phase II, randomized, multicenter, open-label study designed to assess the safety and tolerability of concomitant chemotherapy with low-dose temozolomide during whole brain radiation and later on at 14 days on/14 days…
- Trial name
- NCT00266812
- Testing
- Temozolomide and radiotherapy, Whole brain radiotherapy
- Volunteers
- 35 people
- Sponsor
- Merck Sharp & Dohme LLC
PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Clinical Evaluation of 177Lu-PSMA-VG01 Injection in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer （mCRPC）
This is a phase I clinical trial conducted in participants with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT07660211
- Testing
- 177Lu-PSMA-VG01
- Where
- China
- Volunteers
- 10 people
- Sponsor
- VitsGen Therapeutics Inc.
Solid Tumor, Positron-Emission Tomography(PET)
Phase I Clinical Trial of 68Ga-NOTA-SNA002
The clinical trial was a single-center, dose-increasing, open trial.In this clinical trial, 68Ga-NOTA-SNA002 was injected intravenously to observe its safety tolerance, radiation absorption dose, distribution characteristics…
- Trial name
- NCT05989997
- Testing
- 68Ga-NOTA-SNA002
- Where
- China
- Volunteers
- 17 people
- Sponsor
- SmartNuclide Biopharma
Non-small Cell Lung Cancer, Brain Metastases
Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation
The purpose of this study is to evaluate the safety and tolerability of Icotinib at different dose levels in combination with whole brain radiotherapy for NSCLC patients with brain metastases and EGFR mutation.
- Trial name
- NCT01516983
- Testing
- icotinib, Whole brain radiotherapy
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Brain Metastases
Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases
In this dose-escalation study, the safety and tolerability of escalating dose levels of RRx-001 administered intravenously twice a week in subjects with brain metastases receiving whole brain radiation therapy (WBRT) will be…
- Trial name
- BRAINSTORM (NCT02215512)
- Testing
- RRx-001 + WBRT
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- EpicentRx, Inc.
Healthy Subjects (HS)
A Study to Evaluate the Safety, Biodistribution, Internal Radiation Dosimetry, and Effective Dose of DaTSCAN™ Ioflupane (123I) Injection in Chinese Healthy Volunteers.
This is a phase 1, single-centre, single-group, nonrandomized, noncomparative, open-label, single-dose study to evaluate the safety, biodistribution, internal radiation dosimetry, and effective dose of DaTSCAN™ ioflupane (123I)…
- Trial name
- NCT04564092
- Testing
- DaTSCAN™ Ioflupane (123I) Injection
- Where
- China
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Non-small Cell Lung Cancer Stage III
A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)
This study seeks to establish the recommended Phase 2 dose (RPTD) of veliparib in combination with concurrent paclitaxel/carboplatin-based chemoradiotherapy (CRT) and consolidation with paclitaxel/carboplatin-based chemotherapy…
- Trial name
- NCT02412371
- Testing
- Paclitaxel, Carboplatin, Veliparib
- Where
- 12 sites in United States
- Volunteers
- 48 people
- Sponsor
- AbbVie
Diagnostic Imaging
Evaluation of the Diagnostic Potential of BAY1006578 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of BAY1006578 in Healthy Volunteers
PET (positron emission tomography) imaging with BAY1006578 for investigation of diagnostic potential in probable Alzheimer Disease patients versus healthy volunteers and radiation dosimetry in healthy volunteers.
- Trial name
- NCT01153607
- Testing
- BAY1006578
- Where
- 2 sites in Finland, Sweden
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Lantheus Biosciences Ltd.
Prostate, Cancer
Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device
The VOYAGER Study is an interventional, non-randomized, single-arm, dose escalation trial with the goal of determining the safety of TheraSphere PCa device in patients with clinically localized prostate cancer across US-based…
- Trial name
- VOYAGER (NCT06192758)
- Testing
- TheraSphere PCa
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Boston Scientific Corporation
Breast Cancer With Metastatic Bone Disease
Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid
The aim of this prospective, randomized, open-label, multicentric clinical study is to assess the effícacy and tolerability of zoledronic acid 4 mg IV infused over 15 minutes every 4 weeks for a total of 6 infusions, in…
- Trial name
- NCT00172029
- Testing
- Zoledronic acid
- Where
- 7 sites in Turkey (Türkiye)
- Volunteers
- 116 people
- Sponsor
- Novartis
Chronic Effect of Ultraviolet Radiation on Photoaged Skin, Dermatologic Disorders
Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging
The purpose of this study is to determine whether a one-time injection of allogeneic mesenchymal bone marrow cells is safe and beneficial in the treatment of photodamage on the face.
- Trial name
- NCT01771679
- Testing
- Allogeneic Mesenchymal Bone Marrow Cells
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Stemedica Cell Technologies, Inc.
Glioblastoma
Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients
The purpose of this study is to obtain first, exploratory information on the safety and efficacy of (i) olaptesed pegol in combination with radiation therapy in patients with newly diagnosed glioblastoma of unmethylated MGMT…
- Trial name
- GLORIA (NCT04121455)
- Testing
- Olaptesed pegol, Radiotherapy, Bevacizumab
- Where
- 6 sites in Germany
- Volunteers
- 117 people
- Sponsor
- TME Pharma AG
Solid Tumors
M3541 in Combination With Radiotherapy in Solid Tumors
This dose-escalation study evaluated the safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and explore antitumor activity of M3541 in combination with fractionated palliative radiotherapy (RT) in participants with…
- Trial name
- NCT03225105
- Testing
- M3541, Palliative Radiotherapy (RT)
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
In this study, adults with non-small-cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and squamous-cell carcinoma of the head and neck (SCCHN) will be treated with TAK-676 and pembrolizumab following radiotherapy.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT04879849
- Testing
- Pembrolizumab, TAK-676, Image-guided radiation therapy
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Takeda
Acute Radiation Syndrome
BIO 300 Oral Powder Safety and Pharmacokinetics
Open-label, single ascending dose and multiple single dose study in healthy volunteers to evaluate the safety and pharmacokinetics of BIO 300 Oral Powder (BIO 300).
- Trial name
- NCT04650555
- Testing
- BIO 300 Oral Powder
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Humanetics Corporation
Bone Metastases in the Thorax
FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases in the Thorax
The purpose of this study is to assess toxicities of FLASH radiotherapy treatment and pain relief in subjects with painful thoracic bone metastases.
- Trial name
- FAST-02 (NCT05524064)
- Testing
- FLASH Radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Varian, a Siemens Healthineers Company
Head and Neck Cancer
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy
The purpose of this study is to evaluate the efficacy, safety and tolerability of palifermin on the incidence of oral mucositis in subjects with locally advanced head and neck cancer receiving postoperative radiotherapy.
- Trial name
- NCT00540332
- Testing
- palifermin
- Sponsor
- Swedish Orphan Biovitrum
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected…
- Conditions
- GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors
- Trial name
- NCT07165132
- Testing
- RYZ401
- Where
- 15 sites in United States, Canada
- Volunteers
- 104 people
- Sponsor
- RayzeBio, Inc.